Rossari Biotech Ltd

- There is no mention in the transcript of any current or planned fundraising through debt or equity. - The company is focusing on internal CAPEX of around Rs. 120-130 crore this year, primarily for capacity expansion and project modifications, funded through existing resources. - No indications or discussions about raising fresh capital via equity or debt instruments were noted during the Q2 FY25 earnings call. - The management appears confident about meeting growth and margin targets using their operational cash flows and existing funds. - Emphasis is on optimizing capacity utilization, new product initiatives, and expanding export markets rather than seeking external funding.

- Ongoing CAPEX projects at Unitop and Dahej facilities with about Rs. 60 - Rs. 65 crore already spent. - A similar amount expected to be spent over the next 6 months. - Projects to be commissioned in Q3, Q4 of the current year and Q1 of next year. - Total project budget enhanced by Rs. 18.25 crore, now up to Rs. 146.25 crore due to design modifications. - Additional acquisition of 39,101 sqm land adjacent to Dahej facility for future expansion. - These investments aimed at serving high-growth segments such as agrochemicals, home & personal care, and specialty chemicals. - Expected asset turn of roughly 3x-4x from these investments. - Establishment of Rossari Biotech Trading FZE in UAE for export market distribution and sales. - Acquisition of 100% equity in Unistar Thai Company Limited, focusing on specialty chemical manufacturing.

- The company expects low to mid double-digit top-line growth, aiming for around 12%-13% revenue growth for the full year FY25 (Page 9, Page 12). - Export sales are a key growth driver, having grown 32% in H1 FY25 and currently constituting about 25% of overall sales. Exports are expected to outpace domestic growth further (Page 3, Page 9). - Volume growth is expected in the Textile segment domestically (~6%-7% YoY growth) despite pricing pressure (Page 5). - Animal Health & Nutrition business anticipates a much stronger second half, with Q3 and Q4 traditionally being strong quarters, aided by new products and infrastructure improvements (Page 6, Page 11). - New capacities coming online in the next 3-4 months and ongoing CAPEX projects will enhance production, aiming for asset turns of 3x-4x (Page 11, Page 12). - Improvement in margin and utilization expected as new products and capacities scale up (Page 12).

- The company expects low to mid double-digit top-line growth, targeting around 12%-13% revenue growth for FY25. - EBITDA margins are anticipated to remain stable around 13.2%-13.5% in the near term, with potential for improvement as new products scale up and capacity utilization improves. - Export business is a key growth driver, with exports growing 32% in H1 FY25 and expected to outpace domestic growth further. - Operational improvements and new CAPEX projects (Rs. 60-65 crore spent, similar amount planned) targeting asset turns of 3x-4x will enhance return ratios and future profitability. - Margin compression due to high freight costs and raw material pricing pressure is expected to normalize over time as freight costs stabilize and pricing adjustments occur. - Institutional cleaning and Animal Health segments are expected to contribute to future growth, with improved collections and new products anticipated. - Overall, management is confident about sustaining earnings growth with new initiatives and geographic expansion.

- The transcript does not explicitly mention the current or expected order book or pending orders in quantitative terms. - Discussions highlight growth in exports with a 32% increase in H1 FY25, indicating a healthy demand pipeline internationally. - Domestic growth is softer, particularly in home care non-agri and textile exports impacted by geopolitical issues in Bangladesh and Egypt. - There is an ongoing focus on expanding export markets including Europe, South America, Middle East, Turkey, Bangladesh, Nepal, and Sri Lanka. - New product development internally consumed initially, with plans to offer to domestic and export markets as capacity expands. - Management expects improved order inflow from Bangladesh within 1-2 months as banking/payment issues improve. - Overall growth is expected at 12%-13% top-line for the year, implying a steady order intake to support this forecast.